Epigenic Therapeutics is a clinical‑stage company developing next‑generation gene modulation therapies using its proprietary EPIREG™ epigenome regulation platform. Its lead clinical programs include EPI‑003 for a functional cure of chronic hepatitis B and EPI‑001 for hypercholesterolemia, and the company also advances multiple preclinical programs. Epigenic has developed EpiTax™, an in‑vivo LNP delivery platform to target the liver and extrahepatic organs, and an AIAID™ platform that uses a foundational epigenetics model, multi‑agent virtual labs, and AI‑driven protein design to accelerate discovery and optimization. The company states the approach enables durable, specific gene silencing via DNA methylation and histone modification without DNA cleavage, positioning it as an alternative to traditional gene editing. Epigenic plans to use recent financing to accelerate clinical development and strengthen its technology platforms. Epigenic Therapeutics develops gene editing/modulation therapies by regulating the epigenetic genome to treat a variety of diseases. Its proprietary EPIREG™ platform uses AI algorithms to identify optimized CRISPR‑Cas components that regulate expression of one or multiple genes without changing DNA sequence. The company combines EPIREG™ with a proprietary lipid nanoparticle (LNP) delivery system that has demonstrated ex vivo and in vivo delivery in metabolic, cardiovascular, viral hepatitis, ocular and rare disease models. Epigenic has multiple product candidates targeting metabolic, cardiovascular, viral hepatitis, ocular and rare diseases and plans to advance two lead programs into preclinical development and early clinical validation. Led by CEO Bob Zhang and founded in 2021 in Shanghai, the company intends to expand its leadership team and continue investing in its core technology platforms. It recently raised capital in a Series A to fund those activities. Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies by regulating the epigenetic genome rather than altering DNA sequence. Its proprietary platform uses in-house AI algorithms to identify optimized CRISPR-Cas components that modulate one or multiple target genes without DNA cleavage. The company says this approach can avoid risks associated with DNA cleavage, including off-target effects, short half-life, and patient compliance challenges. Epigenic combines the editing platform with a patented lipid nanoparticle (LNP) delivery system that has been shown to deliver medicines precisely and efficiently ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models. Epigenic intends to validate its epigenetic editing advances in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations. The company recently raised capital to support these plans and is led by CEO Bob Zhang.

Total raised

$112M

Funding rounds

3

Latest round

Series B

Latest activity

Sep 2025